Share on StockTwits

Furiex Pharmaceuticals (NASDAQ:FURX) SVP Gail Frances Mcintyre sold 1,746 shares of the company’s stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $104.58, for a total transaction of $182,596.68. Following the completion of the sale, the senior vice president now directly owns 28,122 shares in the company, valued at approximately $2,940,999. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Furiex Pharmaceuticals (NASDAQ:FURX) traded down 0.34% on Thursday, hitting $104.63. 331,694 shares of the company’s stock traded hands. Furiex Pharmaceuticals has a one year low of $32.05 and a one year high of $121.97. The stock has a 50-day moving average of $102.1 and a 200-day moving average of $77.80. The company’s market cap is $1.131 billion.

Furiex Pharmaceuticals (NASDAQ:FURX) last announced its earnings results on Wednesday, May 7th. The company reported ($1.25) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.63) by $0.62. The company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $10.01 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was down 83.7% on a year-over-year basis. On average, analysts predict that Furiex Pharmaceuticals will post $-2.57 earnings per share for the current fiscal year.

Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.